Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
news
BLOCK LISTING SIX MONTHLY RETURN
Information
provided on this form must be typed or printed electronically and provided
to an ris.
Date: __14 Feb_____2008
|
Name of applicant: |
Napo Pharmaceuticals, Inc |
|||
|
Name of scheme: |
Blocklisting covers: 2006 Equity Incentive Plan 2001 Equity Incentive Plan |
|||
|
Period of return: |
From: |
9 June 2007 |
To: |
14 February 2008 |
|
Balance of unallotted securities under scheme(s) from previous return: |
3,119,198 common shares: 646,324 in 2006 Equity Incentive Plan 2,472,874 in 2001 Equity Incentive Plan |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
0 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
20,000 in 2001 Equity Incentive Plan |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
3,099,198 common shares: 646,324 in 2006 Equity Incentive Plan 2,452,874 in 2001 Equity Incentive Plan |
|||
|
Name of contact: |
Charles Thompson, Chief Financial Officer |
|
Telephone number of contact: |
(001) + 650 616 1903 |